NO20051390L - Fremgangsmate for behandling av pasienter med massivt blodtap - Google Patents

Fremgangsmate for behandling av pasienter med massivt blodtap

Info

Publication number
NO20051390L
NO20051390L NO20051390A NO20051390A NO20051390L NO 20051390 L NO20051390 L NO 20051390L NO 20051390 A NO20051390 A NO 20051390A NO 20051390 A NO20051390 A NO 20051390A NO 20051390 L NO20051390 L NO 20051390L
Authority
NO
Norway
Prior art keywords
blood loss
procedure
treating patients
massive blood
massive
Prior art date
Application number
NO20051390A
Other languages
English (en)
Inventor
Richard E Dewoskin
Marc D Doubleday
Steven A Gould
George A Hides
Original Assignee
Northfield Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northfield Lab filed Critical Northfield Lab
Publication of NO20051390L publication Critical patent/NO20051390L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

S a m m e n d r a g Fremgangsmåter for behandling av et pattedyr som lider av massivt blod- tap, som omfatter å administrere til pattedyret en polymerisert hemoglobinløsning.
NO20051390A 2002-10-03 2005-03-16 Fremgangsmate for behandling av pasienter med massivt blodtap NO20051390L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41593502P 2002-10-03 2002-10-03
PCT/US2003/031377 WO2004037279A1 (en) 2002-10-03 2003-10-03 Method for treating patients with massive blood loss

Publications (1)

Publication Number Publication Date
NO20051390L true NO20051390L (no) 2005-05-30

Family

ID=32176456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051390A NO20051390L (no) 2002-10-03 2005-03-16 Fremgangsmate for behandling av pasienter med massivt blodtap

Country Status (11)

Country Link
US (1) US7291592B2 (no)
EP (1) EP1553968A4 (no)
JP (1) JP2006502231A (no)
CN (1) CN1703235A (no)
AU (1) AU2003272827B2 (no)
CA (1) CA2499459A1 (no)
MX (1) MXPA05003340A (no)
NO (1) NO20051390L (no)
RU (1) RU2325924C2 (no)
WO (1) WO2004037279A1 (no)
ZA (1) ZA200502307B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049707A1 (en) * 2003-08-29 2005-03-03 Ferree Bret A. Cemented artificial disc replacements
WO2003059162A1 (en) * 2002-01-15 2003-07-24 Broad Of Regents, The University Of Texas System Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures
WO2007087570A2 (en) 2006-01-24 2007-08-02 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
WO2008009635A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
RU2361608C1 (ru) * 2008-03-18 2009-07-20 Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм" Кровезаменитель с функцией переноса кислорода, фармацевтическая композиция (варианты)
RU2452519C1 (ru) * 2011-03-25 2012-06-10 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ компенсации глобулярного объема крови и иммуномодулирующего воздействия при трансплантации
US11504417B2 (en) 2017-07-18 2022-11-22 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464814A (en) * 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5854209A (en) 1995-03-23 1998-12-29 Biopure Corporation Method for oxygenating tissue having reduced red blood cell flow
US5955581A (en) * 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5084558A (en) * 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US6271351B1 (en) * 1995-03-23 2001-08-07 Biopure Corporation Method for preserving a hemoglobin blood substitute
US20020065211A1 (en) * 1995-03-23 2002-05-30 Biopure Corporation Increasing function of organs having reduced red blood cell flow
US6150507A (en) * 1995-03-23 2000-11-21 Biopure Corporation Method for producing a purified hemoglobin product
US5895810A (en) * 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US6288027B1 (en) * 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5691452A (en) * 1995-03-23 1997-11-25 Biopure Corporation Method for preserving a hemoglobin blood substitute
US5691453A (en) * 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
CN1129608C (zh) * 1996-03-28 2003-12-03 诺思菲尔德试验室公司 制备非细胞血红细胞代用品的方法和仪器
US5890852A (en) * 1998-03-17 1999-04-06 Emerson Electric Company Thread cutting die and method of manufacturing same

Also Published As

Publication number Publication date
EP1553968A4 (en) 2009-06-24
CN1703235A (zh) 2005-11-30
US20040067876A1 (en) 2004-04-08
CA2499459A1 (en) 2004-05-06
WO2004037279A1 (en) 2004-05-06
US7291592B2 (en) 2007-11-06
ZA200502307B (en) 2005-11-30
EP1553968A1 (en) 2005-07-20
MXPA05003340A (es) 2005-07-05
RU2005113240A (ru) 2005-12-10
AU2003272827B2 (en) 2009-03-19
RU2325924C2 (ru) 2008-06-10
AU2003272827A1 (en) 2004-05-13
JP2006502231A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
NO20051390L (no) Fremgangsmate for behandling av pasienter med massivt blodtap
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
NO20052348L (no) Behandling av hemoragisk sjokk
NO20033617D0 (no) Fremgangsmåte for behandling av diabetes mellitus
EA200401525A1 (ru) Способы лечения гепатита (варианты )
NO20044564L (no) Fremgangsmater for behandling av nekrotiserende enterocolit
NO20044562L (no) Fremgangsmater for behandling av tarmslyng
WO2005027839A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
WO2002015920A3 (en) Treatment of hyperproliferative diseases
UA87128C2 (ru) ИММУНОГЛОБУЛИН АНТИ-EрCAM И СПОСОБ ЕГО ВВЕДЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ
DK0749582T3 (da) Fremgangsmåde til diagnosticering af præeklampsi
HUP0500472A2 (hu) Szepszis kezelése kis dózisú szöveti faktor bioszintézis inhibitor (TFPI) beadásával
WO2003087159A8 (en) Modulators of the notch signalling pathway and uses thereof in medical treatment
BR0211400A (pt) Tratamento de distrofia muscular com células de sangue do cordão
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
WO2005062706A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2003094933A3 (en) Use of lanthanum for the treatment of hypercalcemia and bone metastasis
SE0200198D0 (sv) New use
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
DK1152760T3 (da) Anvendelse af 4-aminopyridin til behandling af perifere neuropatier
DK1133314T3 (da) Protein C til behandling af seglcellesygdom og thalassæmi
DK1581227T3 (da) Fremgangsmåde til behandling af nyresvigt
WO2004060135A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application